Category: Partners

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center

FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (“PeriNess”), has entered into a Clinical Study Agreement (the “Agreement”) to support an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma.

Dr. Ron Ram, Professor of Medicine and Head of the Bone Marrow Transplantation Unit at the Tel Aviv Sourasky Medical Center (“Sourasky Center”), will act as the principal investigator of the study.

The primary objective of this study is to explore the safety and tolerability of DNase I in combination with anti-CD19 CAR T therapy in subjects with stable or progressive large B-cell lymphoma when DNase I is given in an adjuvant setting. Secondary objectives include efficacy to be evaluated by the measure of complete response rate post CAR T infusion, duration of response and overall survival. The study has the potential for a strong translational component with a complex assessment of biomarker response and analysis of anti-CD19 CAR T expansion and persistence.

“Our data suggests that the degradation of Neutrophil Extracellular Traps (NETs) by DNase I plays a crucial role in maintaining CAR T-cell function and preventing premature CAR T-cell exhaustion. Our preclinical studies conducted show that co-administration of DNase I with anti-CD19 CAR T cells significantly reduce tumor burden, delay tumor relapse and substantially prolong survival compared to the anti-CD19 CAR T cell monotherapy groups in various syngeneic and xenogeneic experimental models of lymphoma and leukemia,” stated Alexey Stepanov, PhD, Institute Investigator at the Scripps Research Institute, and a member of Xenetic’s Scientific Steering Committee.

“Progression of large B cell lymphoma (LBCL) is the major obstacle for the success of CAR T therapies, with approximately 40-60% of the patients relapsing in the first year, and 25-35% within 3 months after CAR T infusion, depending on the CAR T product used. While patients with partial or complete response before CAR T infusion have a 1-year progression free survival of 60-80%, those with stable or progressive disease at the time of CAR T infusion have a 1-year progression free survival of 20-30%. NETs facilitate several hallmarks of cancer biology at various stages, including progression, invasion, metastasis, immunosuppression, immune escape, and resistance to therapy. A high content of NETs in lymphoma tissue and blood of patients was associated with a negative outcome. The goal of this clinical study is to improve clinical response by administering DNase I to abrogate the negative effects of NETs on the performance of immune system and CAR T cells,” added Dr. Ram.

James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic concluded, “We are pleased with the continued progress of our DNase I program and the expansion of its development in another exploratory study to further evaluate its potential in various oncology indications. We look forward to garnering additional data to realize the full potential of DNase I.”

As previously announced, in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator-initiated studies of recombinant DNase I as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company’s DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase I program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company’s website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “remain,” “focus”, “confidence in”, “potential”, and other words of similar meaning, including, but not limited to, all statements regarding expectations with respect to the Clinical Trial Services Agreement with PeriNess, including statements regarding the proposed investigator-initiated study under such agreement to support an exploratory clinical study of our systemic DNase I candidate in patients with large B-cell lymphoma and the expected objectives and goal of such study, and all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our overall development strategy, the progress of our DNase I program, our expectations regarding further expansion of our body of clinical data, our focus on advancing innovative immune-oncology technologies addressing difficult to treat cancers, the DNase technology improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many cancers, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) the relevance of, or our ability to utilize, the data, if any, from any investigator-initiated exploratory study, (2) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements, including the Clinical Trial Services Agreement with PeriNess; (3) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (4) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (5) failure to realize the anticipated potential of the DNase technologies; (6) the ability of the Company to obtain funding and implement its business strategy; and (7) other risk factors as detailed from time to time in the Company’s reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / July 30, 2025 / While AI tools and platforms are evolving faster than accounting professionals can adapt to them, it is still the people and processes within an organization that make them work. However, when individuals move on, this loss can create gaps within the organization, cracks leading to challenges in maintaining efficiency and continuity. To that end, alexion.ai today comes to market with an all-star executive team to guide the company towards its goal of keeping accounting decentralized, intelligent, and resilient.

Alexion acts as connective tissue across firm systems: normalizing unstructured data, reconciling fragmented context, and building AI-powered memory infrastructure. This foundation enables firm-specific agents to operate with trust, traceability, and nuance.

Alexion is not replacing accountants, they’re amplifying them. Preserving their logic. Codifying their judgment. And transforming individual expertise into shared intelligence that strengthens the entire firm.

In order to guide Alexion.ai’s path and ensure it delivers on all of the promises it makes and the technology it is building, the company has assembled an elite and diverse team of leaders that combine accounting, enterprise SaaS, design, and top-level AI backgrounds.

At the helm as alexion.ai’s CEO and Co-Founder is Lisa Griffith, who spent the last several years taking Laurel.AI to market and growing it to new heights as its head of accounting, go-to-market strategy, and partnerships. But her move to Alexion wasn’t about a product, it was about a pattern.

“I didn’t start with a product idea. I started with a pattern. After years inside firms, listening to partners, operators, and rising talent, I saw what was really eroding: not just efficiency, but continuity. The kind of deep, institutional judgment that lives in people, not platforms. And when those people leave, so does the logic.

Alexion is my response to that pattern. We’re not just building tools-we’re building memory. Infrastructure that captures how firms think, not just what they do. That codifies expertise into reusable logic. That enables AI agents to act with the same nuance and judgment as the professionals they support.

Because firms don’t lose value when someone leaves. They lose value when the way that person reasoned walks out the door with them.”
– Lisa Griffith, CEO & Co-Founder, alexion.ai

For Guthrie Chen, Founder and Chief Visionary Officer of alexion.ai, the journey began with a simple idea: true financial understanding could break down nearly any barrier. His exploration brought him into collaboration with diverse experts, from mathematicians to entrepreneurs, where he saw how their specialized knowledge could be synthesized and automated to build a more accessible financial future for everyone.

“Our focus is on human creativity. AI has already come so far, and we want to build the brain, the ‘accountant’s brain,’ in a way that will evolve the world of accounting and tap into the data at our firms and build data you can trust,” said Chen. “We are making numbers real, as well as understanding each other’s languages and disciplines. You have to have that to build a proper product. Accounting can be very subjective; you have to make sure you aren’t forcing software on someone. As we build our brand and tech, it has to feel adaptive.”

Providing a crucial strategic and operational counterpart to Guthrie and Lisa’s vision is Matt McDonagh, Head of Strategy at Alexion. McDonagh brings a unique perspective forged on Wall Street as an investment banker before he pivoted to technology as an investor and a self-taught data engineer. He applies his expertise in using AI to refine strategy and build the operational backbone for Alexion’s growth.

The core challenge Alexion.ai addresses is data fragmentation. In most firms, institutional wisdom is locked in disconnected silos: scattered across white papers, trapped in internal memos, and separated by disparate accounting systems. This foundational problem became McDonagh’s focus after a pivotal meeting with Guthrie at a Family Office and Blockchain conference in Florida.

Impressed by Guthrie’s accounting background and technological approach, McDonagh was struck by its design philosophy: it was built by an accountant, for accountants. “That perspective was crucial,” McDonagh stated. “It was a tool born from the field. It made me realize the broader opportunity is unifying all of a firm’s existing, fragmented data. We saw AI agents fail because their data is unreliable. We saw an opportunity to transform the industry by aggregating this siloed intelligence. Our goal is to normalize it, creating a single source of truth that empowers everything else.”

Alexion.ai’s leadership team is rounded out by Head of Design Kris Andrews, Head of Product Minza Zahid, and Head of Finance Brian Sholley. Silicon Valley legends in Machine Learning and software engineering are working with the Alexion team to develop the technical roadmap to bring the power of AI to accounting. The company is also supported by an All-Star Advisory Board, including Gary L. Boomer, Rafael Casas, and Dr. Sean Stein Smith.

For more information, please reach out to Lisa Griffith.

Lisa Griffith
CEO
lisa@alexion.ai
5107100587

SOURCE: alexion.ai

View the original press release on ACCESS Newswire

• First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire’s new direct-to-consumer shopping experience

ESTERO, FL / ACCESS Newswire / July 31, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending supplement delivery technology, today announced the rollout of its new e-commerce solution, buzzbomb.buzz with BUZZ BOMB™ as its featured launch product. This new seamless direct-to-consumer shopping experience allows consumers to order BUZZ BOMB™ on the Aspire platform and have them shipped directly to their door with access to exclusive promotions, and customer support. To celebrate the launch, customers who register for Aspire’s e-commerce site will have first access to special pricing, free shipping offers, and other promotions. The site features an introductory sample pack of four flavors as well as 30-packs in various configurations.

“We are excited to launch our new BUZZ BOMB™ e-commerce website in the U.S., which marks a significant step forward for the brand and will provide consumers with a seamless and personalized shopping experience,” said Kraig Higginson, Interim Chief Executive Officer of Aspire. “This launch enables us to offer our advanced sublingual pre-workout supplement-designed to help athletes and fitness enthusiasts maximize their performance potential -directly to customers across the nation and at a competitive price. Together with our significant presence and marketing plans at two of the largest fitness conventions in early August, we are confident that the launch of our e-commerce site will further accelerate the brand’s growth among active and fitness-minded consumers, helping us achieve our goal of providing one of the most advanced caffeine delivery formulas on the market.”

Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential. BUZZ BOMB™, offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed. Unlike pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB™ is sprinkled under the tongue-without any mixing with water or hassle–for immediate effect.

About the Aspire Targeted Oral Delivery Platform

Aspire’s technology delivers fast-acting supplement formulations which have been developed by using our patent-pending methodology, and “trade secret” process. The technology’s new mechanism of action allows for rapid sublingual absorption. The benefits of “rapid absorption” are to provide rapid impact in more precise quantities.

About Aspire Biopharma, Inc.

Headquartered in Estero, Fl., Aspire Biopharma has developed a disruptive technology that can deliver supplements and drugs rapidly and precisely. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as “estimate,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “potential,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. This marketing authorization follows the Positive Opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The authorization is valid in all 27 EU member states, as well as Iceland, Liechtenstein and Norway. Following the EC decision, doses will be available for eligible populations ahead of the 2025-2026 vaccination season.

“We appreciate the EC’s timely review and are pleased that our updated COVID-19 vaccine will be available to protect the public against currently circulating strains,” said Stéphane Bancel, Chief Executive Officer of Moderna. “COVID-19 continues to impact individuals and healthcare systems globally and we encourage people to speak to their healthcare providers about receiving an updated vaccine.”

The marketing authorization follows guidance from various global health authorities, which recommended that COVID-19 vaccines be updated to target the LP.8.1 strain for the 2025-2026 vaccination season.

Moderna’s COVID-19 vaccines have been generally well-tolerated. The most common solicited local adverse event for Moderna’s COVID-19 vaccines is injection site pain. The most common solicited systemic adverse events include headache, fatigue, myalgia and chills.

Additional regulatory applications for Moderna’s updated COVID-19 vaccines targeting LP.8.1 are under review around the world.

About Moderna

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

Spikevax®is a registered trademark of Moderna.

Moderna Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the availability of Moderna’s COVID-19 vaccines in EU Member State, Iceland, Liechtenstein and Norway; and the tolerability of Moderna’s COVID-19 vaccines. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

Moderna Contacts

Media:
Chris Ridley
Head of Global Media Relations
+1 617-800-3651
Chris.Ridley@modernatx.com

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.

View the original press release on ACCESS Newswire

NEW YORK CITY, NEW YORK / ACCESS Newswire / July 30, 2025 / New to The Street, the nation’s premier financial media platform for emerging public companies, proudly announces a major media partnership with NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI). Under this agreement, NeOnc will be featured in a 12-part national broadcast series, with exclusive monthly interviews airing on Bloomberg Television and Fox Business Network. The series will also include earned media distribution, commercial rotation across national networks, and outdoor billboard campaigns in the most visible financial corridors in the U.S.

This partnership launches at a pivotal time for NeOnc Technologies, following two significant corporate milestones:

• The signing of a Letter of Intent to acquire breakthrough intellectual property (IP) for brain cancer treatment, positioning the company at the forefront of neuro-oncology innovation;

• The execution of a $50 million definitive strategic partnership with Quazar Investment, accelerating NeOnc’s operational and clinical development roadmap.

Breakthrough Science Meets Breakthrough Exposure

The integrated media campaign includes:

• 12 Long-Form Network Broadcast Interviews from the Nasdaq and NYSE studios on Bloomberg TV and Fox Business as sponsored programming.

• More than 300 Monthly Commercial Spots across targeted investor and innovation-focused time blocks.

• Earned Media Coverage on major U.S. networks via NewsOut™, including CBS, NBC, and ABC affiliates.

• Iconic Billboard Placements in Times Square (Nasdaq Tower and Reuters Boards), NYC Financial District shelters, and premium taxi tops.

• Digital Amplification via YouTube and social platforms:

  • New to The Street TV Channel: youtube.com/@NewtotheStreetTV

  • NewsOut Channel: youtube.com/@newsoutchannel

Executive Commentary

“NeOnc is entering a new era, not only in terms of medical science but also visibility in the public markets. Their latest IP acquisition and $50 million partnership with Quazar reflect serious momentum,” said Vince Caruso, Founder and CEO of New to The Street. “We’re proud to provide a media platform that matches their global ambitions and innovations with real-world distribution, every month.”

About NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI)

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas.

NeOnc’s lead therapeutics, NEO100™ and NEO212™, are currently in Phase II human clinical trials and advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California, consisting of issued patents and pending applications related to NEO100, NEO212, and other candidates from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
To learn more, visit https://www.neonc.com.

About New to The Street

Since 2009, New to The Street has been a leading force in financial media, showcasing public and private companies through its unmatched mix of national television broadcasts, digital syndication, and social media reach. With over 3.2 million subscribers on the New to The Street TV YouTube channel and a combined following of more than 511,000 across LinkedIn, Facebook, Instagram, and X, the platform delivers consistent visibility to investors, industry leaders, and the general public.

New to The Street offers more linear “real TV” broadcast distribution than any other outlet in the space, with long-running placements across Bloomberg TV, Fox Business Network, and other national platforms. Its “Opportunities to Consider™” segments and in-depth executive interviews have become a trusted source for market-moving narratives, emerging growth stories, and thought leadership across finance, tech, biotech, and beyond.

Learn more:

• Website: https://www.newtothestreet.com

• YouTube: youtube.com/@NewtotheStreetTV

• NewsOut Channel: youtube.com/@newsoutchannel

Media Contact:

Monica Brennan
Head of Communications, New to The Street
Monica@NewToTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / July 30, 2025 / D. Boral ARC Acquisition I Corp. (the “Company”) today announced the pricing of its initial public offering of 25,000,000 units at a price of $10.00 per unit for total gross proceeds of $250,000,000. The units are expected to begin trading on The Nasdaq Global Market under the ticker symbol “BCARU” on July 31, 2025. Each unit consists of one of the Company’s Class A ordinary shares and one-half of one redeemable public warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Once the securities comprising the units begin separate trading, the Company expects that its Class A ordinary shares and warrants will be listed on The Nasdaq Global Market under the symbols “BCAR” and “BCARW,” respectively. The offering is expected to close on August 1, 2025, subject to customary closing conditions.

The Company was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an acquisition opportunity in any business, industry, sector or geographical location, the Company intends to identify and acquire a business where the Company believes its management teams’ and affiliates’ expertise will provide a competitive advantage, including the technology, healthcare, and logistics industries.

D. Boral Capital LLC is acting as sole book-running manager for the offering. The Company has granted the underwriters a 45-day option to purchase up to 3,750,000 additional units at the initial public offering price to cover over-allotments, if any, which, if exercised in full, would bring the total gross proceeds of the offering to $287,500,000.

The offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from D. Boral Capital LLC: Attn: 590 Madison Avenue 39th Floor, New York, NY 10022, or by email at dbccapitalmarkets@dboralcapital.com, or by telephone at (212) 970-5150, or from the U.S. Securities and Exchange Commission’s (the “SEC”) website at www.sec.gov.

A registration statement on Form S-1 relating to these securities was declared effective by the SEC on July 30, 2025. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s initial public offering (“IPO”) and the gross proceeds thereof, the anticipated use of the net proceeds from the IPO and the search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or at all, that the net proceeds of the offering will be used as indicated or that the Company will ultimately complete a business combination transaction in the sectors it is targeting or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and preliminary prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact

John Darwin, Chief Financial Officer
Email: contact@arc-group.com

SOURCE: D. Boral Capital

View the original press release on ACCESS Newswire